Organised by
Organised by
Cardiologist
University of Dundee
Professor Chim C Lang is Head of Division and Professor of Cardiology at the University of Dundee, with an extensive career in cardiovascular research, clinical trials, and medical education, and numerous awards and fellowships recognizing his contributions to cardiology.
Professor Dr Chim C Lang is a distinguished academic and clinician, currently serving as Head of Division and Professor of Cardiology at the University of Dundee, Ninewells Hospital and Medical School, United Kingdom. He also holds the roles of REF Case Impact Co-Lead for the School of Medicine and Honorary Consultant Cardiologist at NHS Tayside. In addition, he is the Tuanku Muhriz Royal Chair at the National University of Malaysia and Pharmacovigilance Medical Officer at the Tayside Clinical Trial Unit, Tayside Medical Science Centre. Professor Lang has held adjunct and visiting professorships at institutions including the International Medical University in Kuala Lumpur and Columbia University in New York. His academic journey began at Methodist Boys’ School in Kuala Lumpur and Kingswood School in Bath, followed by a Bachelor of Medical Science in Pharmacology, Bachelor of Medicine and Bachelor of Surgery, and Doctorate of Medicine from Dundee University. His MD thesis focused on 'Neurohormones and Sodium homeostasis in Man.' He is a Fellow of the Royal College of Physicians (London and Edinburgh), Academy of Medicine of Malaysia, American College of Cardiology, European Society of Cardiology, Association of Physicians of Great Britain and Ireland, and the Royal Society of Edinburgh. Professor Lang’s career is marked by a series of prestigious awards and recognitions. His undergraduate accolades include the Class Medalist in Pathology, George Ranken Tudhope Prize in Pathology, and Dr RD Campbell Memorial Prize in Laboratory Medicine. His postgraduate honors feature the Pfizer Academic Award, Merck International Fellowship in Clinical Pharmacology, British Pharmacological Society's BrAPP Prize and Medal, American Federation of Clinical Research Trainee Investigator Award, American Society for Clinical Pharmacology and Therapeutics Presidential Trainee Award, International Society of Hypertension in Blacks Fellowship Award, ASEAN Congress of Cardiology Young Investigator Award, Royal College of Physicians of London and Academy of Medicine of Malaysia Award, Tun Razak Award, Fulbright Scholarship, Royal Society of Edinburgh International Exchange Program, and the Desmond Julian Prize from the European Society of Cardiology, among others. He has also been recognized for his mentorship, with his research fellows receiving numerous national and international awards. Professor Lang’s research has had significant impact on clinical practice and policy. His work on BNP and spironolactone contributed to the University of Dundee’s top ranking for research impact in Clinical Medicine in the UK. His studies on ACE inhibitors in aortic valvular disease influenced the 2014 American Heart Association/American College of Cardiology Guidelines. He has advanced understanding in areas such as diabetes and heart failure, obesity and cardiovascular risk, drug-induced long QT syndrome, and the use of health informatics in cardio-metabolic disease management. His research has shaped international guidelines and informed regulatory decisions, including those by the Food and Drug Administration. Notably, his VESUVIUS study provided key data for the UK government’s tobacco control plan and Public Health England’s reports on e-cigarettes. Professor Lang’s research interests encompass the clinical physiology and pharmacology of congestive heart failure, pharmacogenetics, drug repurposing for cardiovascular diseases, diabetic heart disease, and aortic valvular disease. He leads and collaborates on numerous international research consortia and clinical trials, including the European Commission FP-7 and Horizon 2020 projects, MRC-funded PRIME collaboration, and the JDRF-funded SOPHIST trial. He has secured substantial research funding from organizations such as the Chief Scientist Office, Juvenile Diabetes Research Fund, British Heart Foundation, Wellcome Trust, NIHR, and AstraZeneca. A prolific author, Professor Lang has published extensively in peer-reviewed journals, contributed to books and chapters, and served as Editor-in-Chief and on editorial boards of several scientific journals. He is a frequent invited speaker at national and international conferences, delivering lectures on topics ranging from heart failure and diabetes to pharmacogenetics and clinical trial methodology. His teaching portfolio includes core medical education in cardiology and therapeutics, supervision of undergraduate and postgraduate research students, and examination and evaluation roles at leading universities worldwide. Professor Lang is actively involved in scientific advisory panels, editorial boards, and professional societies. He has held leadership roles in the European Society of Cardiology, British Heart Foundation, and various national and international committees. His administrative contributions span clinical governance, research training, and policy development at local, national, and international levels. Through his multifaceted career, Professor Chim C Lang has made enduring contributions to cardiovascular medicine, research, and education.
2024 Malaysian Society of Hypertension All Right Reserved